Royce & Associates LP Has $7.77 Million Holdings in Profound Medical $PROF

by · The Cerbat Gem

Royce & Associates LP lifted its holdings in Profound Medical (NASDAQ:PROF – Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 990,348 shares of the company’s stock after acquiring an additional 130,442 shares during the quarter. Royce & Associates LP owned approximately 2.73% of Profound Medical worth $7,771,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. TD Waterhouse Canada Inc. raised its position in Profound Medical by 2.9% in the 4th quarter. TD Waterhouse Canada Inc. now owns 77,493 shares of the company’s stock worth $582,000 after purchasing an additional 2,200 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in Profound Medical by 3.8% in the 4th quarter. Thompson Davis & CO. Inc. now owns 216,735 shares of the company’s stock worth $1,706,000 after purchasing an additional 8,015 shares during the last quarter. MMCAP International Inc. SPC raised its position in Profound Medical by 2.0% in the 3rd quarter. MMCAP International Inc. SPC now owns 500,859 shares of the company’s stock worth $2,449,000 after purchasing an additional 10,000 shares during the last quarter. National Bank of Canada FI raised its position in Profound Medical by 7.3% in the 3rd quarter. National Bank of Canada FI now owns 172,883 shares of the company’s stock worth $845,000 after purchasing an additional 11,704 shares during the last quarter. Finally, Royal Bank of Canada raised its position in Profound Medical by 3.5% in the 1st quarter. Royal Bank of Canada now owns 435,997 shares of the company’s stock worth $2,537,000 after purchasing an additional 14,795 shares during the last quarter. Institutional investors own 47.86% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Profound Medical has a consensus rating of “Hold” and a consensus target price of $12.00.

Get Our Latest Stock Report on Profound Medical

Profound Medical Price Performance

PROF stock opened at $6.90 on Friday. The company has a 50 day moving average price of $6.55 and a 200 day moving average price of $6.87. Profound Medical has a fifty-two week low of $3.76 and a fifty-two week high of $8.95. The stock has a market capitalization of $250.75 million, a PE ratio of -5.56 and a beta of 0.73.

Profound Medical (NASDAQ:PROF – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.05. The company had revenue of $5.34 million during the quarter, compared to analysts’ expectations of $4.85 million. Profound Medical had a negative net margin of 206.76% and a negative return on equity of 78.88%. As a group, equities analysts expect that Profound Medical will post -0.88 earnings per share for the current fiscal year.

Profound Medical Profile

(Free Report)

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.

Featured Articles